Ticker: PDSB

PDS Biotechnology Corporation (NASDAQ: PDSB) - quick take PDSB is a clinical‑stage immunotherapy company with no product revenue. Management has raised capital in 2025 (February equity offering and an April Securities Purchase Agreement) and used proceeds to retire prior loan facilities and fund...

PDS Biotechnology Corporation (NASDAQ: PDSB) Overview PDS Biotechnology Corporation is a clinical-stage immunotherapy company focused on developing targeted immunotherapies for cancer and infectious diseases. They utilize their proprietary Versamune® platform in various applications and are advan...